Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), will present at the 43rd Annual J.P. Morgan Healthcare ...

Hold Biocon 320-put option as stock may drop to ₹350, with potential for premium increase. Contact [email protected] ...

Biocon stock price has broken out from the upper band of a Symmetrical Triangle formation, indicating a positive movement.

Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price.

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

Biocon’s subsidiary, Biocon Biologics Limited (BBL), has announced the completion of its first year as a fully integrated ...

This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concerning ...

Zomato slips on Jefferies' downgrade, Biocon rallies on USFDA approval and Jefferies upgrade, ONGC gains as CLSA names it a ...

Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...

Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc. and Janssen Sciences Ireland ...

Optimism for Biocon is fuelled by the green light for its Bengaluru biologics unit, paired with the USFDA approval for the launch of its Stelara biosimilar for autoimmune disorders, ...

At around 10:45 am, shares of the company were trading 7.22% higher at Rs 384.50 on the Bombay Stock Exchange (BSE).